Botanix Pharmaceuticals reports $10.1M quarterly net revenue

·       Botanix Pharmaceuticals delivered Q4 net revenue of $10.1 million, representing a 45% sequential increase.

·       The company's share price fell 4.35% to $0.022 despite the revenue growth.

·       Growth was driven by expanding Sofdra prescription volume and higher gross-to-net yields.

Botanix Pharmaceuticals (ASX:BOT) generated $10.1 million in net revenue for the fourth quarter of fiscal 2026.

This result represents a 45% increase from the $6.9 million reported in the previous quarter.

Gross sales for the period rose to $46.7 million as prescription shipments reached 33,358 units.

Botanix stated that operating cash outflow improved to $10.6 million while cash reserves reached $36.6 million.

Following the announcement, the Botanix Pharmaceuticals share price was down at $0.021.

The company develops and sells Sofdra, an FDA-approved topical gel for excessive underarm sweating.

Earlier in the fiscal year, Botanix completed a capital raise to support its commercial platform expansion.